1. Why Shandong Pharmaceutical Manufacturing Matters

In the geography of China's pharmaceutical industry, Shandong has long been a defining pillar. In 2023, above-scale pharmaceutical industrial enterprises in Shandong Province achieved total revenue of approximately 285.3 billion yuan, placing the province second nationally, behind only Jiangsu. In the China Pharmaceutical Industry Top 100 ranking, Shandong had 25 pharmaceutical companies listed in 2023, and still had 12 on the 2024 list — consistently among the highest in the country.

Multiple factors underpin this position: Shandong's status as a major agricultural and chemical province provides a reliable supply of basic inputs for active pharmaceutical ingredient (API) manufacturing; coastal port infrastructure supports API exports; and decades of accumulated industrial capacity have allowed the province to simultaneously sustain four major sub-industries — chemical drugs, traditional Chinese medicine (TCM), biologics, and medical devices.

In 2022, above-scale pharmaceutical industrial enterprises in the province generated revenue of 349.59 billion yuan and total profit of 50.48 billion yuan, with profit accounting for 11.3% of total provincial industrial profit — making pharmaceuticals one of the highest-margin sectors in Shandong's industrial economy.

2. Geographic Cluster Distribution

Pharmaceutical manufacturing enterprises are present in all 16 cities of Shandong, but core clusters are relatively concentrated.

Jinan is the center of gravity for R&D and biologics. As of 2023, Jinan hosts 1,058 biomedical enterprises, the most in the province. QILU Pharmaceutical is headquartered here and has been accelerating its push into innovative drugs and biosimilars, particularly in the oncology space.

Yantai is distinguished by its full-spectrum biomedical ecosystem, with total primary business revenue in the sector exceeding 100 billion yuan for four consecutive years (per Yantai municipal government data). The city has established a vertical chain from APIs to formulations to biologics, supported by cold-chain logistics and export infrastructure.

Weihai specializes in medical devices. Weigao Group, the city's flagship enterprise, recorded revenue of approximately 13 billion yuan through its listed subsidiary Weigao General Medical in 2024, with product lines covering infusion, orthopedics, and hemodialysis.

Zibo concentrates a large number of API and chemical pharmaceutical manufacturers. Xinhua Pharmaceutical, headquartered here, is a globally significant supplier of analgesic/antipyretic APIs.

Heze has been aggressively building biomedical industrial parks in recent years. With 704 biomedical enterprises as of 2023, it shows the most pronounced catch-up trajectory among Shandong's cities.

Qingdao hosts 934 biomedical enterprises and has carved out a niche in marine biomedical products and high-end diagnostic reagents.

As of the end of 2023, Shandong's total biomedical enterprise count reached 5,924, including 4,704 medical device companies, 408 chemical drug producers, 182 API manufacturers, 261 TCM enterprises, and 53 biologic product companies.

3. Leading Enterprise Landscape

QILU Pharmaceutical is Shandong's largest pharmaceutical enterprise by revenue. In 2024, it ranked third in the China Pharmaceutical Industry primary revenue Top 100 — its tenth consecutive appearance in the national top ten. From a generics base, it has been steadily moving into innovative drugs and biosimilars, with products such as bevacizumab and rituximab biosimilars now included in the national medical insurance catalog.

Dong-E-E-Jiao is the most recognizable Shandong brand in TCM. In 2024, the company reported revenue of 5.921 billion yuan, up 25.57% year-on-year; net profit attributable to shareholders reached 1.557 billion yuan, up 35.29%. The company's premium positioning strategy — steadily raising average selling prices on its core donkey-hide gelatin products — has yielded gross margins significantly above peer TCM manufacturers.

Xinhua Pharmaceutical, based in Zibo, is a major global supplier of analgesic/antipyretic APIs and chemical formulations. In 2024, revenue reached 8.466 billion yuan, up 4.51%, but net profit fell 5.33% to 470 million yuan — reflecting intensifying price competition in the API segment and the challenge of maintaining market share in an environment of volume-based procurement.

Lukang Pharmaceutical focuses on antibiotic APIs and formulations, with international business reaching 98 countries. Its 2024 total sales revenue grew 15% year-on-year, indicating continued traction in overseas markets.

Weigao Group stands apart in the medical devices space. Its listed subsidiary Weigao General Medical (HK) reported approximately 13 billion yuan in 2024 revenue; Weigao Blood Purification (newly listed on the A-share main board in 2024) targets hemodialysis with performance parameters benchmarking against international leaders; and Weigao Orthopaedics recorded 1.453 billion yuan in 2024 revenue, up 13.18%.

Lunan Pharmaceutical focuses on specialty formulations and TCM injections, with a significant market position in cardiovascular products.

4. Upstream and Downstream Structure

Shandong's pharmaceutical manufacturing supply chain is relatively self-contained — a structural advantage over many other provinces.

On the upstream side, Shandong's well-developed basic chemicals sector provides a reliable supply of pharmaceutical intermediates for API production. For TCM raw materials, Jin Yinhua (honeysuckle) in Linyi, Peony Bark in Heze, and Salvia in Weifang have developed into large-scale cultivation bases, with some enterprises extending traceability back to the cultivation source. A cluster of local equipment suppliers serves the chemical pharmaceutical and bioreactor fermentation segments.

On the downstream side, Shandong enterprises sell through both domestic hospital channels and export routes. Domestically, hospital-channel sales are heavily influenced by national volume-based procurement (VBP), which has driven sustained price compression on high-volume generic drugs. For exports, the primary focus is APIs; Asia, Europe, and Latin America are the key destination markets, and companies including Lukang, Xinhua, and Weigao have established meaningful international distribution networks.

5. Challenges and Strategic Direction

Several structural pressures are converging on Shandong's pharmaceutical manufacturing sector.

The continued expansion of volume-based procurement is the most immediate profit headwind. Xinhua Pharmaceutical's 2024 pattern of revenue growth without profit growth illustrates the dynamic clearly — key products were priced down to defend market share, compressing gross margins by more than five percentage points. This is not a Shandong-specific problem but rather the shared condition of generic drug manufacturers across China.

A second challenge relates to API export market uncertainty. The global trend toward supply chain diversification has prompted some multinational pharmaceutical companies to seek multiple sources, but China's scale and cost advantages in API production are difficult to displace in the near term. Shandong's export enterprises face pricing pressure in negotiations rather than the risk of structural market exit.

On the strategic transformation front, provincial policy has explicitly designated biomedical as one of the "Ten Strong Industries" for 2024–2025, with targets to establish 20 hundred-billion-yuan health industry parks and bring total provincial pharmaceutical output past 420 billion yuan by 2025. At the enterprise level, QILU Pharmaceutical's innovative drug investment is among the largest of any domestic private pharmaceutical company; Weigao is unlocking asset value through a multi-subsidiary listing strategy; and Dong-E-E-Jiao has traced a distinct path for TCM consumer goods through premium positioning.

For upstream sales teams supplying pharmaceutical raw materials, equipment, packaging, or testing reagents to Shandong pharmaceutical manufacturers, Tianxia Gongchang provides a searchable directory of pharmaceutical factories by region and sub-industry, with decision-maker contact information, enabling efficient identification of procurement entry points across Shandong's pharmaceutical cluster.

Data Sources

  • Tianxia Gongchang (Shandong pharmaceutical manufacturing factory directory and industry data)
  • Shandong Provincial Bureau of Statistics, "2024 Shandong Province National Economic and Social Development Statistical Bulletin"
  • Yaozhi.com, "Shandong Province Biomedical Industry Development Bulletin (2023)"
  • Dong-E-E-Jiao Co., Ltd., 2024 Annual Report
  • Xinhua Pharmaceutical Co., Ltd., 2024 Annual Report
  • Shandong Lukang Pharmaceutical Co., Ltd., 2024 Annual Report
  • China Pharmaceutical Industry Top 100 (2024 edition), China Pharmaceutical Industry Information Center
  • Yantai Municipal Government, Yantai Biomedical Industry Full-Spectrum Primary Business Revenue Data
  • Shandong Provincial Government, "Ten Strong Industries Action Plan (2024–2025) — Health Industry Action Plan"
  • PHIRDA, "Above-Scale Enterprise Revenue Ranking for Pharmaceutical Manufacturing: Which Province Leads in Biomedicine?"